The purpose of the Training and Career Development Program of the Primary Immune Deficiency Treatment Consortium (PIDTC) is to provide career development that will enhance education at the clinical postdoctoral level. By training clinical and translational investigators specifically in the area of primary immune deficiency (PID), the cadre of physicians and scientists involved in elucidating the pathogenesis of these disorders and in developing and applying improved therapies will be augmented. Clinical investigators caring for patients with PID require a complex set of skills, including knowledge of the biology of immune reconstitution and transplant immunology, familiarity with diagnosis and medical management of patients with PID, and expertise in hematology, infectious diseases, genetics and critical care of ill patients undergoing hematopoietic cell transplantation. The PIDTC brings together specialists from across the US and Canada and with its research activities provides a unique platform to train new investigators in the course of disseminating knowledge to providers, patients and families. The goal of PIDTC training grants is to provide support for research at the level of the clinical post-doctoral fellow. This career development support will enrich the pool of talented clinicians caring for patients with PID and advance translational research in the field.

Public Health Relevance

Primary immune deficiencies (PIDs) are rare, life-threatening inherited defects in the immune system. The Training and Career Development portion of the Primary Immune Deficiency Treatment Consortium (PIDTC)'s will help to achieve one of the major objectives of the PIDTC by promoting research by young investigators of the causes and treatment of the primary immune deficiencies so that there will be a continuum of expertise throughout North America in this field

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-HOP-Y)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Burbank, Allison J; Shah, Shaili N; Montgomery, Maureen et al. (2016) Clinically focused exome sequencing identifies an homozygous mutation that confers DOCK8 deficiency. Pediatr Allergy Immunol 27:96-8
Cowan, Morton J (2016) The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID? Expert Rev Clin Immunol 12:1007-9
Griffith, Linda M; Cowan, Morton J; Notarangelo, Luigi D et al. (2016) Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol 138:375-85
Chan, Alice Y; Punwani, Divya; Kadlecek, Theresa A et al. (2016) A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70. J Exp Med 213:155-65
De Ravin, Suk See; Wu, Xiaolin; Moir, Susan et al. (2016) Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 8:335ra57
Jackson, Shaun W; Scharping, Nicole E; Jacobs, Holly M et al. (2016) Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation. J Immunol 197:4529-4534
Punwani, Divya; Kawahara, Misako; Yu, Jason et al. (2016) Lentivirus Mediated Correction of Artemis-deficient Severe Combined Immunodeficiency. Hum Gene Ther :
Punwani, Divya; Zhang, Yong; Yu, Jason et al. (2016) Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B. N Engl J Med 375:2165-2176
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Chinen, Javier; Notarangelo, Luigi D; Shearer, William T (2016) Advances in clinical immunology in 2015. J Allergy Clin Immunol 138:1531-1540

Showing the most recent 10 out of 64 publications